Company Overview - SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-targeted, high-potency immunoglobulins (IgGs) to treat and prevent immune and autoimmune disorders [2] - The company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach aimed at delaying onset and potentially preventing disease progression [2] - SAB BIO utilizes advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, enabling the generation of a diverse repertoire of specifically targeted, high-potency human IgGs [2] Upcoming Events - SAB BIO management will participate in the Guggenheim SMID Cap Biotech Conference on February 6, 2025, with a fireside chat scheduled from 2:00 to 2:25 PM ET [1] - The company will also present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 10:00 to 10:30 AM ET [1] - Live webcasts and archived recordings of these events will be available on the SAB BIO investor relations website [1]
SAB BIO to Participate in Upcoming Investor Conferences